Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of ofatumumab in relapsing multiple sclerosis
2023-507906-15-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 37
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Primary endpoints: Proportion of subjects with adverse events, Proportion of subjects with laboratory or vital sign abnormalities and 2 more. Planned start Jan 2019; status: authorised.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-507906-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507906-15-00.